The proportions of hemoglobin types induced in mouse erythroleukemia cells vary with the inducer or combination of inducers, the inducer concentration and the time of induction.
The relative amounts of hemoglobin (Hb) major and Hb minor accumulated during induction of erythrodifferentiation in mouse erythroleukemia (MEL) cells were studied. The ratio of major to minor was found to depend not only upon the inducer tested (as reported previously by others), but also upon the concentration of the inducer and the time of exposure to the inducer as well as the specific cell line of MEL cells studied. At concentrations required for optimal induction of differentiation, certain agents led to the accumulation of predominantly Hb major, but suboptimal concentrations of the same inducers led to predominantly Hb minor accumulation. After a relatively short induction time (2 da) utilizing a given inducer either the level of Hb minor was higher than that of Hb major or the levels of the two Hb's were approximately equal, but after longer induction periods (3-7 da) Hb major was more abundant than Hb minor. In addition, it was found that the three proteases tested induced predominantly Hb minor. The addition of suboptimal concentrations of low molecular weight inducers acted synergistically with a given protease to produce a high yield of Hb-containing cells. When these agents were added singly they induced relatively low Hb major/Hb minor ratios, but when a low molecular weight inducer was added together with a protease in a "synergistic" combination, elevated ratios were induced. The proportions of hemoglobin types induced in MEL cells may be related in part to the intensity of the induction response. In view of these data, classifications of inducers based solely on the ratios of Hb types produced must be guarded.
D000081:Acetamides / Q000494:pharmacology; D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D004357:Drug Synergism; D004920:Erythropoiesis / Q000187:drug effects*; D006133:Growth Substances / Q000145:classification / Q000494:pharmacology*; D006454:Hemoglobins / Q000096:biosynthesis* / Q000145:classification; D004915:Leukemia, Erythroblastic, Acute / Q000097:blood*; D051379:Mice; D008811:Mice, Inbred DBA; D008970:Molecular Weight; D010447:Peptide Hydrolases / Q000494:pharmacology; D013997:Time Factors
D000081:Acetamides; D006133:Growth Substances; D006454:Hemoglobins; D010447:Peptide Hydrolases; C014026:hexamethylene bisacetamide; D004121:Dimethyl Sulfoxide